Aligos Therapeutics (ALGS) Operating Leases (2019 - 2026)

Aligos Therapeutics has reported Operating Leases for 8 years, with the latest figure at $659000.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 84.55% year-over-year to $659000.0; the trailing twelve-month figure through Mar 2026 stood at $659000.0 (down 84.55% YoY), and the FY2025 full-year result was $1.5 million, down 68.2% from the prior year.
• Operating Leases for Q1 2026 stood at $659000.0, down from $1.5 million in the prior quarter.
• The five-year high for Operating Leases was $10.9 million in Q1 2022, with the low at $659000.0 in Q1 2026.
• Historically, Operating Leases has averaged $6.4 million across 5 years, with a median of $7.0 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases grew 6.56% — and 2026, when it slumped 84.55%.
• Aligos Therapeutics' Operating Leases stood at $9.2 million in 2022, then dropped by 16.66% to $7.7 million in 2023, then tumbled by 37.47% to $4.8 million in 2024, then sank by 68.2% to $1.5 million in 2025, then slumped by 56.79% to $659000.0 in 2026.
• The last three Operating Leases figures came in at $659000.0 (Q1 2026), $1.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.